Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target at $25.77

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been given a consensus recommendation of “Hold” by the seventeen analysts that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $25.7692.

MLTX has been the subject of several recent analyst reports. Stifel Nicolaus lowered MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price for the company. in a research report on Monday, September 29th. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 6th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $10.00 target price (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a research note on Monday, September 29th. Finally, BTIG Research raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Friday, January 9th.

MoonLake Immunotherapeutics Trading Up 1.5%

MLTX stock opened at $15.86 on Thursday. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.78 and a beta of 1.21. The firm’s fifty day simple moving average is $14.27 and its two-hundred day simple moving average is $29.34.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.21). During the same period in the previous year, the company posted ($0.56) EPS. As a group, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Buying and Selling

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer directly owned 2,948,577 shares in the company, valued at $44,464,541.16. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the sale, the insider directly owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. This trade represents a 64.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 402,908 shares of company stock worth $5,987,162. Corporate insiders own 12.02% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics in the third quarter worth about $28,000. Bank of America Corp DE raised its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after purchasing an additional 3,166 shares during the period. Covestor Ltd bought a new position in shares of MoonLake Immunotherapeutics during the third quarter valued at approximately $46,000. Finally, BNP Paribas Financial Markets increased its holdings in MoonLake Immunotherapeutics by 18.9% during the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.